Polymorphisms in the IL‐1 gene cluster influence systemic inflammation in patients at risk for acute‐on‐chronic liver failure

Acute‐on‐chronic liver failure (ACLF) in cirrhosis is an increasingly recognized syndrome characterized by acute decompensation, organ failure(s) and high short‐term mortality. Recent findings suggest that an overexuberant systemic inflammation plays a primary role in ACLF progression. In this study, we examined whether genetic factors shape systemic immune responses in patients with decompensated cirrhosis. Six single‐nucleotide polymorphisms (SNPs) in inflammation‐related genes (interleukin [IL]‐1 beta [IL‐1β], rs1143623; IL‐1 receptor antagonist [IL‐1ra], rs4251961; IL‐10, rs1800871; suppressor of cytokine signaling‐3, rs4969170; nucleotide‐binding oligomerization domain‐containing protein 2, rs3135500; and chemerin chemokine‐like receptor 1, rs1878022) were genotyped in 279 patients with cirrhosis with (n = 178) and without (n = 101) ACLF from the CANONIC study of the CLIF consortium. Among these SNPs, we identified two polymorphisms belonging to the IL‐1 gene cluster (IL‐1β and IL‐1ra) in strong association with ACLF. Both SNPs were protective against ACLF; IL‐1β (odds ratio [OR], 0.34, 95% confidence interval [CI], 0.13‐0.89; P < 0.05) and IL‐1ra (OR, 0.58; 95% CI, 0.35‐0.95; P < 0.05) under the recessive and overdominant inheritance models, respectively. These protective SNPs translated into reduced circulating levels of IL‐1β, IL‐1α, IL‐6, granulocyte‐colony stimulating factor, granulocyte‐macrophage colony‐stimulating factor, and C‐reactive protein at enrollment as well as after 7‐14 days of admission. These findings were confirmed in vitro in leukocytes incubated with plasma from patients with decompensated cirrhosis carrying the protective SNP genotypes. Notably, a higher frequency of the protective genotypes was observed in patients without (80%) than in those with (20%) ACLF. Consistently, patients carrying the combined protective genotypes showed a lower 28‐day mortality rate. Conclusion: These data identify two common functional polymorphisms in the IL‐1 gene cluster, which are associated with the inflammatory process related to development of ACLF. (Hepatology 2017;65:202‐216).

[1]  Richard Moreau,et al.  Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.

[2]  J. Silke,et al.  Fight or flight: regulation of emergency hematopoiesis by pyroptosis and necroptosis , 2015, Current opinion in hematology.

[3]  G. Auzinger,et al.  University of Birmingham Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK , 2014 .

[4]  R. Parkhouse,et al.  Insights into the molecular basis of the NOD2 signalling pathway , 2014, Open Biology.

[5]  S. Rajasekaran,et al.  Therapeutic Role of Anakinra, an Interleukin-1 Receptor Antagonist, in the Management of Secondary Hemophagocytic Lymphohistiocytosis/Sepsis/Multiple Organ Dysfunction/Macrophage Activating Syndrome in Critically Ill Children* , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[6]  Vishva M. Dixit,et al.  Mechanisms and Functions of Inflammasomes , 2014, Cell.

[7]  D. Vaux,et al.  RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis , 2014, Cell.

[8]  K. Massey,et al.  Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2 , 2014, Nature Medicine.

[9]  M. Rottenberg,et al.  SOCS3, a Major Regulator of Infection and Inflammation , 2014, Front. Immunol..

[10]  C. Garlanda,et al.  The interleukin-1 family: back to the future. , 2013, Immunity.

[11]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[12]  P. Hedrick What is the evidence for heterozygote advantage selection? , 2012, Trends in ecology & evolution.

[13]  R. Medzhitov Inflammation 2010: New Adventures of an Old Flame , 2010, Cell.

[14]  C. Dinarello Interleukin-1beta and the autoinflammatory diseases. , 2009, The New England journal of medicine.

[15]  J. Singh,et al.  Anakinra for Rheumatoid Arthritis: A Systematic Review , 2009, The Journal of Rheumatology.

[16]  Jayne Jones,et al.  Cytokine Gene Polymorphisms in Heavy Drinkers With and Without Decompensated Liver Disease: A Case-Control Study , 2008, The American Journal of Gastroenterology.

[17]  P. Ridker,et al.  Genetic variants within the interleukin-1 gene cluster, and risk of incident myocardial infarction, and ischemic stroke: a nested case-control approach. , 2008, Atherosclerosis.

[18]  A. Roddam,et al.  Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. , 2008, Rheumatology.

[19]  Peter A. Ward,et al.  Harmful molecular mechanisms in sepsis , 2008, Nature Reviews Immunology.

[20]  D. Raoult,et al.  The two faces of interleukin 10 in human infectious diseases. , 2006, The Lancet. Infectious diseases.

[21]  R. González-Sarmiento,et al.  Interleukin-1 gene cluster polymorphisms and alcoholism in Spanish men. , 2005, Alcohol and alcoholism.

[22]  A. Sher,et al.  Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.

[23]  F. Lammert,et al.  Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. , 2005, Journal of hepatology.

[24]  Ping Wang,et al.  Correlation of polymorphism in the interleukin-1 receptor antagonist gene intron 2 with alcoholic liver disease. , 2005, Hepatobiliary & pancreatic diseases international : HBPD INT.

[25]  M. Manns,et al.  Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[26]  J. Sims,et al.  Annotating genes with potential roles in the immune system: six new members of the IL-1 family. , 2001, Trends in immunology.

[27]  F. Pociot,et al.  Cytokine gene polymorphism in human disease: on-line databases , 1999, Genes and Immunity.

[28]  P. Hertzog,et al.  Recent advances in cytokines, cytokine receptors and signal transduction. , 1998, Cytokine & growth factor reviews.

[29]  S. Saitoh,et al.  Correlation of a polymorphism in the interleukin-1 receptor antagonist gene with hepatic fibrosis in Japanese alcoholics. , 1998, Alcoholism, clinical and experimental research.

[30]  C. Gabay,et al.  Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.

[31]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[32]  C. Gabay,et al.  Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. , 1997, The Journal of clinical investigation.

[33]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[34]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[35]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[36]  G. Tosato,et al.  Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. , 1990, Blood.

[37]  J. Meer,et al.  Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. , 1988, Lymphokine research.

[38]  C. Avnstorp,et al.  Interleukin‐1 , 1987 .